Cancer stem cell as a promising therapeutic treatment

Jazmin Navarro Cisneros


The use of cancer stem cells (CSCs) as therapeutic targets for cancer therapy has gained significant attention in recent years. The importance of CSCs lies in their ability to self-renew and differentiate into multiple cell types, leading to tumor initiation, growth, and resistance to therapy. Several articles have discussed the role of CSCs in tumor progression, and the potential therapeutic strategies for targeting CSCs. There are three articles that will be discussed are as follows. The first article "Targeting cancer stem cell pathways for cancer therapy" by Liqun Yang et al. provides an overview of the signaling pathways that regulate CSCs and discusses potential therapeutic strategies for targeting these pathways. The article highlights the latest advances in our understanding of CSC biology and discusses potential new drug targets and treatment strategies, which can guide future research and drug development efforts. The second article "Cancer stem cell: target for anti-cancer therapy" by Carol Tang et al. discusses the importance of targeting CSCs as a promising approach for developing effective cancer therapies. The article highlights the current state of knowledge regarding the signaling pathways and molecular mechanisms that regulate CSCs. And lastly, the third article "Cancer Stem Cells: Implications for Cancer Therapy" by Isidro Sánchez-Garca et al. covers the difficulties in creating efficient CSC-based medicines and underlines the requirement for a deeper comprehension of the molecular processes that control CSCs. While the potential of targeting CSCs for cancer therapy is promising, several challenges still need to be addressed, including the identification and isolation of CSCs, the development of efficient CSC-based medicines, and the containment of good outcomes for cancer patients. Nonetheless, the continued research and development in this field provide hope for the future of cancer therapy.

Full Text:



  • There are currently no refbacks.